N4 Pharma UK Ltd.
N4 Pharma is a pre-clinical stage specialist pharmaceutical company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company aims to transform drug delivery through its innovative silica nanoparticle technology, with a focus on RNA therapeutics, vaccines, and gene therapy. N4 Pharma's lead program, N4 101, is an oral anti-inflammatory treatment for inflammatory bowel disease, showcasing the platform's potential. The company is building a robust preclinical data set and working towards first-in-human clinical data to support licensing deals and partnerships.
Industries
Nr. of Employees
small (1-50)
N4 Pharma UK Ltd.
Products
Silica nanoparticle nucleic acid delivery platform
A fused silica nanoparticle platform with irregular surface architecture that binds and protects nucleic acid payloads, supports co‑loading of multiple sequences, and is designed to enable various administration routes including oral, IV, SC and IM.
Oral dual‑loaded nucleic acid therapeutic (preclinical)
An oral capsule formulation containing dual‑loaded nucleic acids intended to target gut macrophages and reduce TNF‑α activity for treatment of inflammatory bowel disease; currently in preclinical development.
Ocular anti‑fibrotic siRNA product (preclinical)
A siRNA therapeutic delivered via a peptide‑lipid delivery system intended to silence MRTF‑β to reduce postoperative ocular fibrosis; demonstrated reduced mRNA expression and improved surgical bleb survival in animal studies.
Peptide‑lipid nucleic acid delivery platform
A peptide and lipid based carrier system that mimics viral entry for targeted delivery and efficient endosomal release of nucleic acids into cells; used to support development of injectable siRNA products.
Silica nanoparticle nucleic acid delivery platform
A fused silica nanoparticle platform with irregular surface architecture that binds and protects nucleic acid payloads, supports co‑loading of multiple sequences, and is designed to enable various administration routes including oral, IV, SC and IM.
Oral dual‑loaded nucleic acid therapeutic (preclinical)
An oral capsule formulation containing dual‑loaded nucleic acids intended to target gut macrophages and reduce TNF‑α activity for treatment of inflammatory bowel disease; currently in preclinical development.
Ocular anti‑fibrotic siRNA product (preclinical)
A siRNA therapeutic delivered via a peptide‑lipid delivery system intended to silence MRTF‑β to reduce postoperative ocular fibrosis; demonstrated reduced mRNA expression and improved surgical bleb survival in animal studies.
Peptide‑lipid nucleic acid delivery platform
A peptide and lipid based carrier system that mimics viral entry for targeted delivery and efficient endosomal release of nucleic acids into cells; used to support development of injectable siRNA products.
Services
Platform licensing and partnerships
Licensing of nucleic acid delivery platform and collaboration opportunities for development and commercialization of partner assets.
Preclinical proof‑of‑concept studies
Design and execution of in vitro and in vivo studies to demonstrate delivery, target knockdown, efficacy and safety of nucleic acid therapeutics delivered using nanoparticle or peptide-lipid carriers.
CMC strategy and contract management advisory
Strategic CMC advice for transitioning substances and formulations to clinical manufacturing, including selection and oversight of contract organisations.
Platform licensing and partnerships
Licensing of nucleic acid delivery platform and collaboration opportunities for development and commercialization of partner assets.
Preclinical proof‑of‑concept studies
Design and execution of in vitro and in vivo studies to demonstrate delivery, target knockdown, efficacy and safety of nucleic acid therapeutics delivered using nanoparticle or peptide-lipid carriers.
CMC strategy and contract management advisory
Strategic CMC advice for transitioning substances and formulations to clinical manufacturing, including selection and oversight of contract organisations.
Expertise Areas
- Nanoparticle-based nucleic acid delivery
- siRNA therapeutic development
- Oral delivery formulation for biologics
- Preclinical in vivo efficacy testing
Key Technologies
- Silica nanoparticle delivery
- Peptide-lipid delivery systems
- siRNA therapeutics
- Lyophilisation and enteric capsule formulation